Deutetrabenazine is a medicine used to treat uncontrolled body movements caused by Huntington's disease or by tardive dyskinesia. It's taken as a pill. It works by lowering the amount of dopamine, a brain chemical that can trigger these extra movements.
Every report comes from a Lived member, sent anonymously.
Have you tried Austedo (Deutetrabenazine) for Tardive Dyskinesia?
Deutetrabenazine, sold as Austedo and Austedo XR, is a prescription medicine that reduces involuntary movements in adults with two conditions. The first is chorea, the sudden, jerky, dance-like movements of Huntington's disease, an inherited illness that gradually breaks down nerve cells in the brain. The second is tardive dyskinesia, uncontrollable movements of the face, tongue or other body parts that can develop after taking medicines that block dopamine, such as antipsychotics or the anti-nausea medicine metoclopramide. Austedo and Austedo XR contain the same medicine. Austedo is a tablet usually taken twice a day, while Austedo XR is an extended-release tablet taken once a day. Deutetrabenazine belongs to a group called VMAT2 inhibitors, which also includes the older drug tetrabenazine and the drug valbenazine. In the tardive dyskinesia trials, most people kept taking their antipsychotic, so it can be added without giving up a medicine that is controlling a mental health condition.
Dopamine is a chemical messenger that, among other roles, helps the brain control movement. Nerve cells store dopamine in tiny sacs before releasing it, and a transporter protein called VMAT2 (vesicular monoamine transporter 2) loads it into those sacs. Once the body converts deutetrabenazine into its active forms, they block VMAT2, so nerve cells hold and release less dopamine. Turning down dopamine signaling in the brain's movement circuits is believed to be how it calms the extra movements, although the precise mechanism is not known. It also lowers stores of serotonin and norepinephrine, messengers that help regulate mood and alertness. Deutetrabenazine is a modified version of tetrabenazine. Some of its hydrogen atoms are replaced with deuterium, a heavier form of hydrogen, which slows the body's breakdown of the drug so it lasts longer and can be taken less often.
Deutetrabenazine is a tablet taken by mouth. Austedo XR is taken once a day, with or without food. Regular Austedo is taken with food, and once the daily total reaches 12 mg it is split into two doses. Either tablet must be swallowed whole, not chewed, crushed or broken. Treatment usually starts at 12 mg a day and is raised in small steps about once a week until the movements are well controlled or side effects get in the way, up to a usual maximum of 48 mg a day. A four-week starter pack of Austedo XR lays out the first increases. The ceiling is lower, 36 mg a day, for people whose bodies break the drug down slowly, either because of their genes or because they take certain antidepressants (see Interactions & Warnings). People switching from tetrabenazine stop it and start deutetrabenazine the next day at a dose matched to their previous one. If a dose is missed, take it when you remember unless the next dose is nearly due, and do not take two doses to make up for one. After a gap of more than a week, check with the prescriber before restarting, because the dose usually has to be built up again from a lower level.
Sleepiness and tiredness are the most common side effects and the ones most likely to limit how high the dose can go. In the Huntington's disease trial, diarrhea, dry mouth and trouble sleeping were also more common than with placebo; in the tardive dyskinesia trials, cold-like symptoms and insomnia were the most frequent. Until the dose is stable and you know how it affects you, avoid driving or operating dangerous machinery. Because it reduces dopamine, deutetrabenazine can cause movement problems of its own. Parkinsonism means slowness, stiffness, tremor, shuffling or unsteady walking, and it has led to falls; it usually appears within two weeks of starting or raising the dose and has generally cleared after the drug was stopped. Akathisia is an intense inner restlessness and urge to keep moving. In Huntington's disease, these effects can be hard to tell apart from the illness itself. Contact the prescriber right away if either develops, since lowering the dose often helps. Rarely, medicines that reduce dopamine trigger neuroleptic malignant syndrome, a dangerous reaction that has been reported with tetrabenazine but not so far with deutetrabenazine. High fever with severe muscle stiffness, confusion, heavy sweating or a fast or irregular heartbeat needs emergency medical care, and the medicine should be stopped.
For people with Huntington's disease, deutetrabenazine carries the FDA's most serious (boxed) warning: it can increase depression and suicidal thoughts and behavior. Depression and suicide risk are already higher in Huntington's disease, so the prescriber weighs how much the chorea interferes with daily life against that risk. The medicine is not used in someone who is suicidal or whose depression is untreated or not well treated. Patients, families and caregivers should watch for new or worsening depression, thoughts of harming oneself, or unusual changes in behavior, and tell the prescriber right away. Some combinations are ruled out. Deutetrabenazine is not taken together with tetrabenazine or valbenazine, which act the same way; with reserpine, an older drug that also blocks VMAT2 and must be stopped at least 20 days beforehand; or with MAO inhibitors (monoamine oxidase inhibitors), a group that includes some antidepressants such as phenelzine and the Parkinson's medicine rasagiline, or within 14 days of stopping one. It is also not used by people with liver impairment. The antidepressants paroxetine, fluoxetine and bupropion slow the breakdown of deutetrabenazine and can roughly triple the level of its active forms, which is why the daily dose is capped at 36 mg with them. Antipsychotics and other dopamine-blocking drugs can raise the chance of parkinsonism, restlessness and neuroleptic malignant syndrome, and alcohol or other sedating medicines add to the drowsiness. Deutetrabenazine can lengthen the QT interval, a measure of how the heart's electrical system resets between beats, though at recommended doses the change is not considered clinically significant. It is avoided in people born with long QT syndrome or with a history of abnormal heart rhythms, and fainting or a racing or irregular heartbeat should be reported. There is little information about its safety in pregnancy, so anyone pregnant or planning a pregnancy should discuss it with the prescriber.
Improvement builds as the dose is raised step by step over several weeks. In the main Huntington's disease trial, people reached their working dose over about eight weeks, at an average of about 40 mg a day, and about half rated their overall symptoms much or very much better, compared with one in five on placebo. In tardive dyskinesia, movements eased more than with placebo at 24 and 36 mg a day, while 12 mg a day was not clearly better than placebo. The benefit lasts only while the medicine is taken. In the Huntington's trial, chorea returned to its starting level within a week of stopping. Deutetrabenazine can be stopped without tapering, but after a break of more than a week the dose has to be built up again. Follow-up visits check how much the movements have improved and look for sleepiness, mood changes, restlessness and stiffness. In Huntington's disease, the prescriber also reassesses from time to time whether the medicine is still needed. The illness itself can bring changes in mood, thinking and stiffness that are hard to separate from side effects, and chorea sometimes lessens on its own over time; lowering or pausing the dose can help show which is which.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Austedo (Deutetrabenazine), what you've noticed, or ask the community a question.